Analysis Of Income And Expense [Abstract]

Cinclus Pharma Holding AB - Filing #5879290

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Royalty income
4 580 SEK
5 959 SEK
Material income and expense [abstract]
Research and development expense
136 657 SEK
166 678 SEK
Finance income (cost)
2 359 SEK
13 637 SEK
Selling, general and administrative expense [abstract]
General and administrative expense
36 854 SEK
39 562 SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
SEK
165 367 SEK
2 664 SEK
SEK
168 031 SEK
SEK
SEK
205 951 SEK
215 118 SEK
9 167 SEK
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
165 367 SEK
205 951 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.